ERBB2 and cervical squamous intraepithelial neoplasia: In light of the new knowledge, it will be interesting to evaluate if patients with HER2 amplification of the EBV subtype behave as those of the CIN subtype and if patients with HER2 mutations, found mainly in the MSI subtype, are also responsive to the treatment.